Saul Yedgar
Corporate Officer/Principal at The Hebrew University of Jerusalem
Profile
Saul Yedgar is a Professor-Emeritus at The Hebrew University of Jerusalem, where he has been employed since 1982.
He previously worked as the Chief Scientific Officer at Celsus Therapeutics Plc from 2005 to 2011.
Prior to that, he held positions as a Principal at the National Institutes of Health and Institut Curie.
Yedgar received his undergraduate degree from Bar-Ilan University and his doctorate from The Hebrew University of Jerusalem in 1977.
Saul Yedgar active positions
| Companies | Position | Start |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | 31/12/1981 |
Former positions of Saul Yedgar
| Companies | Position | End |
|---|---|---|
Institut Curie
 Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Training of Saul Yedgar
| The Hebrew University of Jerusalem | Doctorate Degree |
| Bar-Ilan University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Institut Curie
Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Commercial Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
- Stock Market
- Insiders
- Saul Yedgar
